Mark Brosius, Senior Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc . (NASDAQ:ISRG), sold 492 shares of the company’s common stock on March 3, 2025, according to a recent SEC filing. The shares were sold at an average price of $573.78, totaling $282,299. This transaction was executed under a pre-established trading plan that complies with SEC Rule 10b5-1, which is set to expire on June 13, 2025.
The filing also detailed other recent transactions by Brosius. On February 28, 2025, he acquired 877 shares through the vesting of restricted stock units. Additionally, transactions on the same day involved the withholding of 2,610 shares to cover tax obligations, valued at $563.77 per share. The company maintains strong financial health, with InvestingPro data showing a current ratio of 4.07 and minimal debt levels.
These activities leave Brosius with a total of 4,056 shares in Intuitive Surgical following the transactions. Want deeper insights into insider trading patterns and comprehensive financial analysis? Access the full Intuitive Surgical InvestingPro Research Report, along with 12 additional ProTips about the company’s valuation and performance metrics.
In other recent news, Intuitive Surgical reported a strong fourth-quarter performance, surpassing expectations with a 10% revenue beat and a 24% earnings per share (EPS) beat. The company also projected a 13-16% year-over-year increase in procedure volume for 2025, aligning with its historical trend of setting conservative initial targets. Analysts from RBC Capital Markets maintained an Outperform rating with a $641 price target, highlighting the upcoming launch of the da Vinci (EPA:SGEF) 5 (dV5) system as a key growth driver. Piper Sandler raised its price target to $670, citing the company’s robust earnings and revenue growth, and noted the potential for gross margins to exceed 70% in the mid-term. Oppenheimer maintained a Perform rating, expressing concerns about market saturation and the pricing of the new dV5 system, despite Intuitive Surgical’s strong financial results and significant distribution agreement in Europe.
Bernstein analysts reiterated an Outperform rating with a $700 price target, pointing to a 38% year-over-year EPS increase and the potential for Intuitive Surgical to exceed its conservative financial guidance in 2025. Truist Securities also updated its outlook, increasing the price target to $666 and maintaining a Buy rating, reflecting optimism about the company’s revenue growth and the anticipated mid-year launch of the dV5 system. These developments underscore Intuitive Surgical’s strong market position and growth potential, with analysts expressing varying degrees of optimism about the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.